Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1810) 1810
Book Chapter (62) 62
Magazine Article (26) 26
Newsletter (16) 16
Newspaper Article (16) 16
Publication (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glatiramer acetate (1703) 1703
humans (1301) 1301
science & technology (1196) 1196
multiple sclerosis (1163) 1163
life sciences & biomedicine (1145) 1145
peptides - therapeutic use (745) 745
neurosciences & neurology (719) 719
female (690) 690
multiple sclerosis - drug therapy (660) 660
clinical neurology (576) 576
adult (569) 569
male (568) 568
immunosuppressive agents - therapeutic use (484) 484
neurosciences (477) 477
neurology (454) 454
interferon-beta - therapeutic use (445) 445
multiple sclerosis, relapsing-remitting - drug therapy (401) 401
middle aged (381) 381
biological and medical sciences (303) 303
animals (301) 301
medical sciences (301) 301
treatment outcome (284) 284
adjuvants, immunologic - therapeutic use (242) 242
immunology (222) 222
multiple sclerosis - immunology (218) 218
immunologic factors - therapeutic use (216) 216
drug therapy (207) 207
magnetic resonance imaging (204) 204
peptides - administration & dosage (191) 191
peptides - pharmacology (191) 191
multiple sclerosis and variants. guillain barré syndrome and other inflammatory polyneuropathies. leukoencephalitis (190) 190
peptides - adverse effects (186) 186
disease progression (185) 185
glatiramer acetate - therapeutic use (180) 180
natalizumab (175) 175
pharmacology & pharmacy (172) 172
interferon beta (168) 168
interferon beta-1a (167) 167
interferon (157) 157
care and treatment (154) 154
abridged index medicus (151) 151
research (143) 143
mice (141) 141
immunosuppressive agents - administration & dosage (140) 140
immunosuppressive agents - adverse effects (139) 139
interferon beta-1b (134) 134
medicine & public health (131) 131
analysis (127) 127
pharmacology. drug treatments (125) 125
young adult (125) 125
time factors (117) 117
immunosuppressive agents - pharmacology (115) 115
copolymer 1 (112) 112
multiple sclerosis - therapy (111) 111
retrospective studies (107) 107
recurrence (106) 106
adolescent (104) 104
health aspects (103) 103
disability evaluation (99) 99
multiple sclerosis - pathology (96) 96
biological response modifiers (94) 94
immunomodulators (94) 94
interferon-beta - administration & dosage (94) 94
multiple sclerosis - physiopathology (94) 94
fingolimod (90) 90
psychiatry (89) 89
multiple sclerosis - diagnosis (88) 88
multiple sclerosis, relapsing-remitting - immunology (85) 85
dosage and administration (83) 83
follow-up studies (82) 82
mitoxantrone - therapeutic use (81) 81
clinical trials as topic (80) 80
general & internal medicine (79) 79
interferon-beta (79) 79
medicine, general & internal (78) 78
brain - pathology (77) 77
clinical trials (77) 77
adjuvants, immunologic - administration & dosage (76) 76
copaxone (76) 76
interferon-beta - adverse effects (76) 76
t-lymphocytes - immunology (74) 74
drug therapy, combination (73) 73
degenerative and inherited degenerative diseases of the nervous system. leukodystrophies. prion diseases (72) 72
prospective studies (72) 72
encephalomyelitis, autoimmune, experimental - drug therapy (70) 70
patients (70) 70
medical research (69) 69
t cells (69) 69
disease models, animal (67) 67
experimental autoimmune encephalomyelitis (67) 67
immunotherapy (66) 66
multiple sclerosis, relapsing-remitting - pathology (66) 66
peptides - immunology (66) 66
aged (65) 65
double-blind method (65) 65
immunomodulation (65) 65
development and progression (64) 64
quality of life (64) 64
acetates (63) 63
cells, cultured (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1768) 1768
Russian (50) 50
Spanish (45) 45
German (42) 42
French (20) 20
Japanese (15) 15
Portuguese (13) 13
Hungarian (12) 12
Polish (6) 6
Chinese (5) 5
Finnish (5) 5
Czech (4) 4
Italian (4) 4
Serbian (2) 2
Dutch (1) 1
Hebrew (1) 1
Norwegian (1) 1
Slovak (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
by Mikol, Daniel D, MD and Barkhof, Frederik, MD and Chang, Peter, PhD and Coyle, Patricia K, MD and Jeffery, Douglas R, MD and Schwid, Steven R, MD and Stubinski, Bettina, MD and Uitdehaag, Bernard MJ, MD and on behalf of the REGARD study group and REGARD Study Grp and REGARD study group
Lancet neurology, ISSN 1474-4422, 2008, Volume 7, Issue 10, pp. 903 - 914
Neurology | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Disability Evaluation | Interferon-beta - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - pathology | Confidence Intervals | Drug Administration Schedule | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Immunologic Factors - administration & dosage | Glatiramer Acetate | Magnetic Resonance Imaging - methods | Male | Treatment Outcome | Disease Progression | Peptides - administration & dosage | Injections, Subcutaneous - methods | Interferon beta-1a | Adolescent | Adult | Female | Retrospective Studies | Medical research | Multiple sclerosis | Care and treatment | Interferon beta | Medicine, Experimental | Comparative analysis | Biological response modifiers | Acetates | Index Medicus | Drugs | Subpopulations | Magnetic resonance imaging | Motivation | copolymer 1 | Clinical trials | Interferon
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
by Carter, Natalie J and Keating, Gillian M
Drugs (New York, N.Y.), ISSN 0012-6667, 2010, Volume 70, Issue 12, pp. 1545 - 1577
Adis-Drug-Evaluations | Glatiramer-acetate, general | Multiple-sclerosis | Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Adjuvants, Immunologic - administration & dosage | Adjuvants, Immunologic - pharmacology | Humans | Glatiramer Acetate | Multiple Sclerosis - immunology | Adjuvants, Immunologic - therapeutic use | Disease Progression | Peptides - administration & dosage | Peptides - therapeutic use | Multiple Sclerosis - drug therapy | Peptides - pharmacology
Journal Article
Details down arrow
3. Equivalence of generic glatiramer acetate in multiple sclerosis: A randomized clinical trial
by Cohen, Jeffrey and Belova, Anna and Selmaj, Krzysztof and Wolf, Christian and Sormani, Maria Pia and Oberyé, Janine and Van Den Tweel, Evelyn and Mulder, Roel and Koper, Norbert and Voortman, Gerrit and Barkhof, Frederik and Giovannoni, Gavin and Radül, Ernst Wilhelm and Völp, Andreas and Glatiramer Acetate Clin Trial and Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group
JAMA neurology, ISSN 2168-6149, 12/2015, Volume 72, Issue 12, pp. 1433 - 1441
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Disability Evaluation | Double-Blind Method | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Treatment Outcome | Young Adult | Magnetic Resonance Imaging | Time Factors | Glatiramer Acetate - therapeutic use | Injections, Subcutaneous | Adolescent | Adult | Female | Multiple Sclerosis - drug therapy | Therapeutic Equivalency
Journal Article
Details down arrow
4. Full Text Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study
by Khan, Omar and Rieckmann, Peter and Boyko, Alexey and Selmaj, Krzysztof and Ashtamker, Natalia and Davis, Mat D and Kolodny, Scott and Zivadinov, Robert
Multiple sclerosis, ISSN 1352-4585, 5/2017, Volume 23, Issue 6, pp. 818 - 829
Glatiramer acetate | low-frequency regimen | annualized relapse rate | safety | relapsing-remitting multiple sclerosis | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Glatiramer Acetate - pharmacology | Recurrence | Double-Blind Method | Follow-Up Studies | Outcome Assessment (Health Care) | Glatiramer Acetate - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Disease Progression | Magnetic Resonance Imaging | Glatiramer Acetate - adverse effects | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adult | Female | Immunosuppressive Agents - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Drugs | Neuroimaging | Multiple sclerosis | Copolymer 1 | Nuclear magnetic resonance--NMR | Magnetic resonance imaging | Gadolinium | Interferon | Substantia grisea | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)
by Anderson, James and Bell, Christine and Bishop, John and Capila, Ishan and Ganguly, Tanmoy and Glajch, Joseph and Iyer, Mani and Kaundinya, Ganesh and Lansing, Jonathan and Pradines, Joel and Prescott, James and Cohen, Bruce A and Kantor, Daniel and Sachleben, Richard
Journal of the neurological sciences, ISSN 0022-510X, 2015, Volume 359, Issue 1, pp. 24 - 34
Neurology | Glatiramer acetate | Drugs | Multiple sclerosis | Generic equivalency | Generic | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Glatiramer Acetate - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Glatiramer Acetate - chemistry | Immunosuppressive Agents - chemistry | Multiple Sclerosis - drug therapy | Therapeutic Equivalency | Polymerization | Drug approval | Biopolymers | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
by Khan, Omar and Rieckmann, Peter and Boyko, Alexey and Selmaj, Krzysztof and Zivadinov, Robert and GALA Study Grp and GALA Study Group
Annals of neurology, ISSN 0364-5134, 06/2013, Volume 73, Issue 6, pp. 705 - 713
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Double-Blind Method | Drug Administration Schedule | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Glatiramer Acetate | Male | Treatment Outcome | Peptides - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - epidemiology | Adult | Female | Immunosuppressive Agents - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized study combining interferon and glatiramer acetate in multiple sclerosis
by Lublin, Fred D and Cofield, Stacey S and Cutter, Gary R and Conwit, Robin and Narayana, Ponnada A and Nelson, Flavia and Salter, Amber R and Gustafson, Tarah and Wolinsky, Jerry S and CombiRx Investigators
Annals of neurology, ISSN 0364-5134, 03/2013, Volume 73, Issue 3, pp. 327 - 340
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Disability Evaluation | Double-Blind Method | Humans | Middle Aged | Glatiramer Acetate | Male | Treatment Outcome | Secondary Prevention | Case-Control Studies | Interferon-beta - therapeutic use | Young Adult | Magnetic Resonance Imaging | Analysis of Variance | Adolescent | Adult | Female | Retrospective Studies | Drug Therapy, Combination | Longitudinal Studies | Peptides - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Clinical trials | Multiple sclerosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Glatiramer Acetate in the Treatment of Multiple Sclerosis
: Emerging Concepts Regarding its Mechanism of Action
by Lalive, Patrice H and Neuhaus, Oliver and Benkhoucha, Mahdia and Burger, Danielle and Hohlfeld, Reinhard and Zamvil, Scott S and Weber, Martin S
CNS drugs, ISSN 1172-7047, 5/2011, Volume 25, Issue 5, pp. 401 - 414
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | Glatiramer-acetate, pharmacodynamics | Immunomodulators, pharmacodynamics | Multiple-sclerosis | Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis | Medical sciences | Neuropharmacology | Pharmacology. Drug treatments | Multiple Sclerosis, Relapsing-Remitting - immunology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Humans | Encephalomyelitis, Autoimmune, Experimental - immunology | Glatiramer Acetate | Male | Peptides - pharmacology | Animals | Neuroprotective Agents - pharmacology | Multiple Sclerosis - immunology | Female | Mice | Immunosuppressive Agents - pharmacology | Disease Models, Animal | Multiple Sclerosis - drug therapy | Glatiramer acetate | Multiple sclerosis | Antigen presenting cells | Physiological aspects | Research | Drug therapy | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Glatiramer acetate for multiple sclerosis
by La Mantia, Loredana and Munari, Luca M and Lovati, Roberta and La Mantia, Loredana
Cochrane library, ISSN 1469-493X, 2010, Volume 2010, Issue 5, pp. CD004678 - CD004678
Recurrence | Multiple sclerosis | Immunosuppressive Agents | Multiple Sclerosis, Chronic Progressive | Peptides | Pharmacological interventions for Multiple Sclerosis | Glatiramer Acetate | Treatment Outcome | Disease Progression | Randomized Controlled Trials as Topic | Neurology | Pharmacological treatments by drug type | Multiple Sclerosis, Relapsing‐Remitting | Medicine General & Introductory Medical Sciences | Immunomodulators | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Multiple Sclerosis, Chronic Progressive - drug therapy | Peptides - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights